AXQ Capital’s AnaptysBio ANAB Stock Holding History

AXQ Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$346K	Buy	+6,883	New	+$389K	0.05%	547
2026 Q2	–	Sell	-4,715	Closed	-$261K	–	984
2026 Q1	$261K	Buy	+4,715	New	+$254K	0.03%	639

Other funds holding ANAB

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pertento Partners London, United Kingdom $2.09B AUM 28.64% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Apis Capital Advisors New York $708M AUM 153.08% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

AXQ Capital's ANAB Position: Q3 2026 in Review

AXQ Capital opened a new position in AnaptysBio (ANAB) in Q3 2026: 6,883 shares worth $346K. The stake represents 0.05% of the portfolio and ranks #547 among its holdings. This is a return to the name: AXQ Capital previously reported a position in ANAB as recently as Q1 2026.

AXQ Capital first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

AXQ Capital held 6,883 shares of AnaptysBio worth $346K as of Q3 2026.
AnaptysBio was a new AXQ Capital position in Q3 2026.
AnaptysBio made up 0.05% of AXQ Capital's portfolio in Q3 2026, its #547 holding.
AXQ Capital first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.